AimwellBio | Intelligence Dashboard

✓Subscription activated
✓Intelligence intake completed
3Dossier generation in progress
4System calibration (2 weeks)
5Continuous intelligence operation

FDA Safety Communication: Updated Guidance on Compounded GLP-1 Receptor Agonists

FDA issued updated safety communication regarding compounded semaglutide products. Compliance implications for practitioners sourcing from 503B pharmacies.

Source: FDA.gov · Credibility: 5/5 · Relevance: High · 2 hours ago
EMA Committee Recommends New Monitoring Requirements for Peptide Therapies

CHMP opinion on post-authorization safety monitoring for novel peptide therapeutics. Affects multi-jurisdictional operations.

Source: EMA.europa.eu · Credibility: 5/5 · Relevance: Medium · 6 hours ago
Clinical Trial Registration: BioTE Medical Phase II Enrollment Opens

Competitor entity BioTE Medical registered new Phase II trial for hormone optimization protocol. Therapeutic overlap detected.

Source: ClinicalTrials.gov · Credibility: 5/5 · Relevance: Medium · 1 day ago
DEA Scheduling Update: Proposed Rule Change for Compounded Tirzepatide

DEA proposed rulemaking would impact compounding pharmacies producing tirzepatide analogs. Comment period closes April 15, 2026.

Source: DEA.gov · Credibility: 5/5 · Relevance: High · 4 hours ago
Competitor Intelligence: Hims & Hers Q1 2026 Earnings Preview

Analyst consensus projects 34% YoY revenue growth driven by GLP-1 telehealth expansion. Market positioning overlap detected.

Source: SEC EDGAR · Credibility: 5/5 · Relevance: Medium · 8 hours ago
Published Research: Long-Term Safety Profile of BPC-157 in Musculoskeletal Applications

Peer-reviewed meta-analysis of 12 studies published in Journal of Peptide Science. Relevant to regenerative medicine practitioners.

Source: PubMed · Credibility: 4/5 · Relevance: Low · 2 days ago

All Signals Regulatory Competitive Clinical Market Research

Intelligence Dossier

Generating...

Download PDF →

✓Executive Summary
✓Regulatory Landscape Overview
✓Competitive Positioning Map
4Clinical Pipeline Analysis
5Market Opportunity Assessment
6Threat & Risk Register
7Strategic Recommendations

Weekly Brief — March 22, 2026
7 pages · Generated March 22 · AWB-B832B333-W12
Weekly Brief — March 15, 2026
7 pages · Generated March 15 · AWB-B832B333-W11

Entities Monitored

8

Alerts This Period

14

Novo Nordisk
GLP-1 market leader. 3 new regulatory filings detected this period. Semaglutide label expansion pending.
Category: Competitor · Threat Level: High · Last Activity: 2 hours ago
Eli Lilly
Tirzepatide franchise expansion. Phase III data readout expected Q2 2026 for obesity co-morbidity indication.
Category: Competitor · Threat Level: High · Last Activity: 6 hours ago
Hims & Hers Health
Telehealth competitor. GLP-1 compounding program under FTC scrutiny. Earnings call April 3.
Category: Competitor · Threat Level: Medium · Last Activity: 1 day ago
FDA CDER
Center for Drug Evaluation and Research. Monitoring compounding guidance updates and enforcement actions.
Category: Regulator · Threat Level: Medium · Last Activity: 4 hours ago
BioTE Medical
Hormone optimization competitor. Phase II enrollment opened. Monitoring clinical development trajectory.
Category: Competitor · Threat Level: Low · Last Activity: 1 day ago
USP (US Pharmacopeia)
Standards body. Monitoring for updated compounding standards and monograph revisions relevant to peptide therapeutics.
Category: Standards Body · Threat Level: Low · Last Activity: 3 days ago

Strategic Intelligence

Competitive Position Analysis — Q1 2026

Real-time competitive landscape monitoring active across all tracked entities. Next strategic brief: April 1, 2026.

12

Entities Tracked

3

Active Threats

87%

Position Confidence

Q2

Roadmap Horizon

Regulatory Compression Risk
FDA compounding guidance timeline accelerating. Potential enforcement action within 90 days could restrict 503B sourcing for GLP-1 products.
Impact: Critical · Probability: 65% · Mitigation: Active
Market Share Erosion — Telehealth Vertical
Hims & Hers and Ro expanding direct-to-consumer GLP-1 access. Price compression detected in 3 geographic markets.
Impact: High · Probability: 78% · Mitigation: Monitoring
Patent Cliff — Semaglutide Composition of Matter
Novo Nordisk core patent expiration creates generic entry opportunity. Timeline: 2031-2032. Biosimilar development programs already initiated.
Impact: Medium · Probability: 90% · Mitigation: Planned

1Accelerate regulatory compliance program before Q2 enforcement window
2Diversify supplier relationships across minimum 3 licensed 503B facilities
3Evaluate differentiation strategy against telehealth incumbents in core markets

Total Seats

25

Enterprise license

Active Users

12

Last 7 days

Departments

4

Connected

SLA Uptime

99.9%

Current period

Regulatory Affairs
5 seats active · Full intelligence access · Last login: 1 hour ago
Business Development
3 seats active · Competitive + Market intelligence · Last login: 3 hours ago
Research & Development
2 seats active · Clinical + Research intelligence · Last login: 6 hours ago
Executive Leadership
2 seats active · Full intelligence access + Strategic briefs · Last login: Today

✓SSO integration configured
✓Data classification policy applied
✓Custom intelligence pipelines active
✓SLA monitoring enabled (99.9% target)

Team Members

12

Active this period

Pending Invites

3

Awaiting acceptance

Engagement Rate

87%

Weekly active

Dr. Sarah Chen
VP Regulatory Affairs · Full Access · Last active: 1 hour ago
Marcus Webb
Director, Business Development · Competitive Intel · Last active: 3 hours ago
Dr. Aisha Patel
Chief Scientific Officer · Research + Clinical · Last active: Today
James Morrison
CEO · Full Access + Strategic Briefs · Last active: 2 hours ago
Pending: 3 Invited Members
R&D team expansion · Invitations sent March 27, 2026 · Awaiting SSO enrollment

Active Pipelines

7

Custom intelligence feeds

Signals / Day

47

Avg. processed

Source Count

142

Active sources

FDA Regulatory Monitor
Real-time FDA.gov, Federal Register, CDER database monitoring. 24 sources active.
Status: Operational · Last signal: 2 hours ago · Cadence: Real-time
Competitive Intelligence Feed
SEC filings, patent databases, clinical trials registry monitoring for 8 tracked competitors.
Status: Operational · Last signal: 4 hours ago · Cadence: Real-time
Clinical Research Scanner
PubMed, ClinicalTrials.gov, preprint servers. Therapeutic area: GLP-1, peptide therapeutics, regenerative medicine.
Status: Operational · Last signal: 6 hours ago · Cadence: Daily
Market & Pricing Intelligence
Pricing databases, pharmacy benefit manager updates, payer coverage changes.
Status: Operational · Last signal: 1 day ago · Cadence: Weekly
International Regulatory
EMA, MHRA, TGA, Health Canada regulatory actions and guidance documents.
Status: Operational · Last signal: 8 hours ago · Cadence: Real-time
State Legislation Tracker
State-level compounding pharmacy legislation, telehealth scope-of-practice changes across 50 states.
Status: Operational · Last signal: 2 days ago · Cadence: Daily
Custom Executive Brief
AI-synthesized executive summary pipeline. Consolidates all feeds into weekly strategic narrative.
Status: Operational · Last generated: March 28, 2026 · Cadence: Weekly

✓Payment method on file
✓Auto-renewal active
✓Next billing date: April 1, 2026

March 2026
Paid · March 1, 2026 · Visa ****6411
February 2026
Paid · February 1, 2026 · Visa ****6411
January 2026
Paid · January 1, 2026 · Visa ****6411

Organization

Meridian Health Sciences

Primary Contact

s.chen@meridianhealth.com

Account ID

AWB-ORG-7A3F

✓Email digest: Enabled (daily)
✓Critical alert notifications: Enabled
✓Dossier auto-generation: Enabled
✓Data retention: 12 months

✓Two-factor authentication: Enabled
✓Session timeout: 30 minutes
✓IP whitelist: Not configured

Cortex Simulate

Market Reaction

Regulatory Response

Stakeholder Sentiment

Simulation Output

Cortex Narrative

Open — Confirmed

Blind — Investigate

Hidden — Strategic Edge

Unknown — Emerging

Intelligence Dashboard

AimwellBio — Sovereign Intelligence Infrastructure